Only 30%–50% TNBC patients present pathologic complete response (pCR) after given the standard neoadjuvant chemotherapy regime (including taxane and anthracyclines), which is significantly lower than HER-2+ breast cancer (von Minckwitz et al., 2012; Cortazar et al., 2014). The gene discussed is ERBB2; the disease is breast carcinoma.